ArticleMicrobial biotechnology2023
Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens.
Article in Microbial biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Antibacterial Efficacy of Recombinant Endolysin S.AgEndo1332 in Combination with Antibiotics against Mastitis-Associated S. aureus in a Mouse Mastitis Model.Probiotics and antimicrobial proteins · 2026Article
- Modular plug-and-play engineering of Klebsiella phages with dual receptor-binding proteins for efficient host range design.Journal of biological engineering · 2026Article
- Antimicrobial Peptide Fusion and Alginate Encapsulation Broaden the Antibacterial Spectrum and Preserve Storage Stability of the EndolysinACS omega · 2026Article
- Directed evolution of phage Romulus in biofilm-embeddedBiofilm · 2026Article
- Targeted elimination of Staphylococcus aureus mastitis infections with synthetic phage-based CRISPR-Cas delivery systems.NPJ biofilms and microbiomes · 2026Article
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- Avian PathogenicVeterinary sciences · 2025Review
- PlyCYU endolysin targetingApplied and environmental microbiology · 2025Article
- Bacteriophage-derived endolysins restore antibiotic susceptibility in β-lactam- and macrolide-resistant Streptococcus pneumoniae infections.Molecular medicine (Cambridge, Mass.) · 2025Article
- Development of Chimera AMP-Endolysin with Wider Spectra Against Gram-Negative Bacteria Using High-Throughput Assay.Viruses · 2025Article
- Characterization of the host specificity of the SH3 cell wall binding domain of the staphylococcal phage 88 endolysin.Archives of microbiology · 2025Article
- Endolysins and membrane-active peptides: innovative engineering strategies against gram-negative bacteria.Frontiers in microbiology · 2025Review
- Endolysin NC5 improves early cloxacillin treatment in a mouse model of Streptococcus uberis mastitis.Applied microbiology and biotechnology · 2024Article
- Emerging strategies for treating medical device and wound-associated biofilm infections.Microbial biotechnology · 2024Review
- Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria.Heliyon · 2024Review
- Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review.Acta veterinaria Scandinavica · 2024Review
- Emerging Approaches for Mitigating Biofilm-Formation-Associated Infections in Farm, Wild, and Companion Animals.Pathogens (Basel, Switzerland) · 2024Review
- Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens.Microbial biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Bacteriophage-derived endolysins are a novel class of antimicrobials known to rapidly kill bacteria, including antibiotic-resistant strains. We here engineered endolysins against the bovine mastitis pathogens Streptococcus uberis, Streptococcus agalactiae and Streptococcus dysgalactiae, also targeting intracellular survival and biofilm formation. For this purpose, high-throughput DNA assembly was used to create a library with >80,000 theoretical endolysin variants for screening of their bacteriolytic activity against Gram-positive isolates from (sub)clinically affected cows. This lytic activity was evaluated by turbidity reduction and time-kill assays in phosphate-buffered saline and pasteurized whole cow's milk to allow a rank up of the most potent leading candidates. A top candidate was selected with a 4.0 log killing efficacy against S. uberis, also showing similar activity against S. agalactiae and S. dysgalactiae. This top candidate eradicated S. uberis biofilm and showed intracellular activity in two bovine mammary epithelial cell lines as was confirmed by confocal microscopy. A potentiating effect on cloxacillin, a beta-lactam penicillin used to intramammarily treat bovine Gram-positive mastitis, was observed for this top candidate endolysin in raw cow's milk from (sub)clinically infected udders. Our in vitro results indicate that engineered endolysins may have a future role as add-on in the treatment of bovine streptococcal mastitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.